After lupus setback, Nektar sticks with immunology but lays off 70% of hometown workforce

Almost exactly a year after Nektar Therapeutics jettisoned 70% of its staff, the biotech is now contracting again. This time, 60% of its San Francisco-based workforce is being laid off in a reorganization that will also see the C-suite rejigged and a tighter focus on immunology.